Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades Tricida to Hold

Needham Downgrades Tricida to Hold

Needham analyst Serge Belanger downgrades Tricida (NASDAQ:TCDA) from Buy to Hold.

byBenzinga Newsdesk

October 25, 2022

1 minute read

Needham analyst Serge Belanger downgrades Tricida (NASDAQ:TCDA) from Buy to Hold.

General
News

Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO

By Benzinga Neuro

October 31, 9:09 PM

Bristol Myers Squibb (NYSE:BMY) has named Christopher Boerner as their new Chair of the Board of Directors and…

BMY

Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $45

By Benzinga Newsdesk

January 9, 7:25 AM

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $40 to $45.

DAWN

Meta Takes Legal Stand, Challenges EU Fee As It Battles Regulatory Scrutiny

By Anusuya Lahiri

February 8, 11:16 AM

Meta Platforms challenges 0.05% supervisory fee for EU Digital Services Act compliance, claiming unfair burden distribution among tech giants.

AAPL

News

Citigroup CFO Mark Mason Says Deals Pipeline Remains Quite Strong Versus Pre-Pandemic Level

By Benzinga Newsdesk

October 14, 9:04 AM

-Reuters

Needham Downgrades Tricida to Hold

Related Posts

Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO

Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $45

Meta Takes Legal Stand, Challenges EU Fee As It Battles Regulatory Scrutiny

Citigroup CFO Mark Mason Says Deals Pipeline Remains Quite Strong Versus Pre-Pandemic Level